Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityTimes Interest Earned

Innate Pharma (IPHA) FCF Margin (2020 - 2024)

Innate Pharma posted quarterly FCF Margin of 51.54% for Q4 2024, up 1052.0% year-on-year from 4.47% in Q1 2024, and up 16.95% on a QoQ basis from 62.06% in Q4 2023.

Innate Pharma (IPHA) has 5 years of FCF Margin data on file, last reported at 51.54% in Q4 2024.

  • For the quarter ending Q4 2024, FCF Margin rose 1052.0% year-over-year to 51.54%; the trailing twelve-month figure through Dec 2024 stood at 46.04% (down 1002.0% YoY), and the FY2025 full-year result was 1892.9%, down 185668.0% from the prior year.
  • FCF Margin for Q4 2024 stood at 51.54%, up from 62.06% in the prior quarter.
  • Across five years, FCF Margin topped out at 3.13% in Q2 2022 and bottomed at 232.88% in Q4 2021.
  • The 5-year median for FCF Margin is 51.54% (2024), against an average of 71.11%.
  • The widest annual swing landed in 2021, when FCF Margin slumped 14231 bps; it then surged 20059 bps in 2022.
  • A 5-year view of FCF Margin shows it stood at 90.57% in 2020, then tumbled by 157 bps to 232.88% in 2021, then soared by 86 bps to 32.28% in 2022, then slumped by 92 bps to 62.06% in 2023, then climbed by 17 bps to 51.54% in 2024.
  • The last three FCF Margin figures came in at 51.54% (Q4 2024), 62.06% (Q4 2023), and 31.56% (Q2 2023), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) FCF Margin (Qtr)
1 Quantum Biopharma 1,638,563.89 Bn 1,638,563.89 Bn - -
2 Alterity Therapeutics 767,934.24 Bn 767,934.20 Bn - -
3 Legend Biotech 2,937.00 Bn 2,936.10 Bn 242.10 Mn -3.98%
4 Nanobiotix 2,226.01 Bn 2,225.95 Bn - -
5 Akari Therapeutics 2,169.69 Bn 2,169.69 Bn - -
6 Vertex Pharmaceuticals 110.41 Bn 103.16 Bn 2.59 Bn 43.35%
7 Regeneron Pharmaceuticals 66.44 Bn 57.69 Bn 3.31 Bn 23.53%
8 Evaxion A 65.44 Bn 65.42 Bn - -
9 Alnylam Pharmaceuticals 39.53 Bn 36.52 Bn 959.66 Mn 4.17%
10 Innate Pharma 199.64 Mn 199.64 Mn - -

Historic Data

Download Data 🔒
DateValue
Dec 31, 2024 -51.54%
Dec 31, 2023 -62.06%
Jun 30, 2023 -31.56%
Dec 31, 2022 -32.28%
Jun 30, 2022 3.13%
Dec 31, 2021 -232.88%
Dec 31, 2020 -90.57%